|
|
|
|
||
Re: Cash $2 per share, price $1.57 I see that beyond QLTI trades below its cash position, it has potential royalties of $19.5 million from Mati Therapeutics, a dispute with Valeant to receive $5 million and of course their leading product QLT091001. For this product they plan to file a marketing authorization application (MAA) with the European
Medicines Agency (EMA) for conditional approval in the 2nd half of
2016. |
return to message board, top of board |